SUTENT® In The First Line Treatment Of Renal Cell Carcinoma (SUNIKA)

Pfizer

Status: Completed

Conditions: Renal Cell Carcinoma

Treatments: Other: Sutent: observational study

Study type: Observational

Funder types: Industry

Identifiers

NCT00460798

A6181115

Details and patient eligibility

About

This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before. The aim of the trial is to increase knowledge about quality of life, safety, efficacy and tolerability under conditions of routine use of Sutent. The individual observation period of each patient will be

1 year.

Full description

The Statistical Analysis Plan provides detailed specification of the analysis

Enrollment: 356 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• First-line treatment in patients with metastatic renal cell carcinoma

Exclusion criteria

• Any previous systemic therapy of renal cell carcinoma except for adjuvant treatment

Trial design

356 participants in 1 patient group

Non-Interventional Study

Treatment:

Other: Sutent: observational study